Drugs / VEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06612944 | Nov 2024 → Nov 2027 expected | myelodysplastic syndrome | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06612944 ↗ |
| Action | Inhibit | “BCL2 inhibitor (VEN)” NCT06612944 ↗ |
| Route | Oral | “400 mg per day orally for one week” NCT06612944 ↗ |
| Target | BCL2 | “BCL2 inhibitor (VEN)” NCT06612944 ↗ |